Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two drugs, digoxin and etanercept. Digoxin is a cardiac glycoside used primarily for the treatment of various heart conditions, including atrial fibrillation and heart failure. It works by inhibiting the sodium-potassium ATPase pump, leading to increased intracellular calcium in cardiac cells and improved contractility. Etanercept is a recombinant fusion protein that acts as a tumor necrosis factor (TNF) inhibitor; it binds to TNF-α and blocks its interaction with cell surface TNF receptors, thereby reducing inflammation. Etanercept is indicated for autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. There are no clinically significant pharmacokinetic or pharmacodynamic interactions between these two drugs when coadministered; both can be safely used together without dosage adjustment[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on digoxin + etanercept.